Need for Streamlined Use of DPP-4 Inhibitors in the Treatment of Type 2 Diabetes

Cardiovascular Diabetology - United Kingdom
doi 10.1186/s12933-016-0379-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
2016English

Use of DPP-4 Inhibitors in Type 2 Diabetes: Focus on Sitagliptin

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2010English

Emerging DPP-4 Inhibitors: Focus on Linagliptin for Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2013English

Pdb81 - Dapagliflozin Is Cost-Effective Compared to DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in the Netherlands

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

DPP-4/SGLT2 Inhibitor Combined Therapy for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Systematic Literature Review of DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus and Renal Impairment

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Qtern: DPP-4 and SGLT2 Inhibitor Combination for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Incretin Mimetics and Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes

European Endocrinology
EndocrineEndocrinologyMetabolismAutonomic SystemsDiabetes
2007English

Combination Therapy With DPP-4 Inhibitors and Pioglitazone in Type 2 Diabetes: Theoretical Consideration and Therapeutic Potential

Vascular Health and Risk Management
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy